Señales en vivo de MDXH | Maximiza tus Ganancias con Getagraph.com

Live Chart Being Loaded With Signals

Commentary (26 abr 2024 @ 16:00):

Stats
Volumen de hoy	26 728.00
Volumen promedio	73 187.00
Capitalización de mercado	67.40M
EPS	$0 ( 2024-03-06 )
Próxima fecha de ganancias	( $-0.300 ) 2024-06-05
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-1.180
ATR14	$0.0230 (0.93%)

Insider Trading

Date	Person	Action	Amount	type
2023-02-03	Mvm Partners, Llc	Buy	1 000 000	Common Stock
2021-11-04	Mvm Partners Llp	Buy	0	Common Stock

INSIDER POWER
100.00
Last 1 transactions
Buy: 1 000 000 \| Sell: 0

Volumen Correlación

Largo: 0.22 (neutral)

Corto: 0.83 (strong)

Signal:(47.563) Same movement expected

MDxHealth SA Correlación

10 Correlaciones Más Positivas

10 Correlaciones Más Negativas

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

MDxHealth SA Correlación - Moneda/Commodity

-0.18
( neutral )

-0.51
( weak negative )

0.00
( neutral )

0.12
( neutral )

-0.11
( neutral )

MDxHealth SA Finanzas

Annual	2023
Ingresos:	$70.19M
Beneficio Bruto:	$39.44M (56.18 %)
EPS:	$-1.660

FY	2023
Ingresos:	$70.19M
Beneficio Bruto:	$39.44M (56.18 %)
EPS:	$-1.660

FY	2022
Ingresos:	$37.05M
Beneficio Bruto:	$19.22M (51.87 %)
EPS:	$-3.16

FY	2021
Ingresos:	$22.24M
Beneficio Bruto:	$10.41M (46.82 %)
EPS:	$-2.40

Financial Reports:

No articles found.

MDxHealth SA

MDxHealth SA, a commercial-stage precision diagnostics company, provides urologic solutions in the United States, the Netherlands, Belgium, Spain, Poland, Italy, rest of European Union, and internationally. Its novel prostate cancer genomic testing solutions are SelectMDx, a non-invasive urine test; and ConfirmMDx, an epigenetic test, which provide physicians with a clinical pathway to identify clinically prostate cancer while minimizing the use of invasive procedures that are prone to complications. The company was formerly known as OncoMethylome Sciences SA and changed its name to MDxHealth SA in October 2010. MDxHealth SA was incorporated in 2003 and is headquartered in Herstal, Belgium.